MedTrace Logo

PR3-AAV Resilient Remission or PRRR

NCT05376319 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2026-05-06

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy and safety of obinutuzumab for the treatment of proteinase 3 Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (PR3-AAV).

Conditions

  • Granulomatosis With Polyangiitis
  • Microscopic Polyangiitis
  • ANCA Associated Vasculitis

Interventions

DRUG

Obinutuzumab

1000 mg per infusion given approximately two weeks apart, on day 1 and on day 15

DRUG

Rituximab

1000 mg per infusion given approximately two weeks apart, on day 1 and on day 15

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Ulrich Specks, MD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-30
Primary Completion
2024-05-07
Completion
2024-05-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05376319 on ClinicalTrials.gov